Definium Therapeutics, Inc. (DFTX) /
The profitability of Definium Therapeutics, Inc. over the past 6 years
Chart Definium Therapeutics, Inc.: operating income, net income, fiscal 2020–2025 Open the chart →Definium Therapeutics, Inc. reported a net loss of $183.79M in fiscal 2025, the latest fiscal year on file. That year it had an operating loss of $166.31M. It reported a loss in all 6 years shown.
Year by year
| Fiscal year | Operating income | Net income |
|---|---|---|
| 2025ended Dec 31, 2025 | -$166.31M | -$183.79M |
| 2024ended Dec 31, 2024 | -$103.92M | -$108.68M |
| 2023ended Dec 31, 2023 | -$93.87M | -$95.73M |
| 2022ended Dec 31, 2022 | -$66.33M | -$56.8M |
| 2021ended Dec 31, 2021 | -$93.85M | -$93.04M |
| 2020ended Dec 31, 2020 | -$33.03M | -$33.94M |
Fiscal years as Definium Therapeutics, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Definium Therapeutics, Inc.
Companies of a similar size
- VSHVishay Intertechnology, Inc.
- SPHRSPHERE ENTERTAINMENT CO.
- OIIOCEANEERING INTERNATIONAL INC
- FINVFinVolution Group
- LAZLAZARD, INC.
Not investment advice. This page shows what Definium Therapeutics, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.